 |
Hepatitis News:
April 2006
New test touted for Hepatitis C victims
"Rockville, Md.-based Celera Genomics said Wednesday it has developed a genetic
test to help determine which Hepatitis C sufferers are at greatest risk."
HIV/HCV coinfected patients have a poorer outcome after starting antiretrovirals
than those who only have HIV
"HIV-positive individuals who are coinfected with hepatitis C virus have poorer
outcomes after starting potent antiretroviral therapy than patients who are only
infected with HIV, according to a nationwide Danish study to be published in the
May 15th edition of Clinical Infectious Diseases (now online)."
Results
Support Dosing Every Two Weeks with Potential for Improved Side Effect Profile
Over Current Therapies
"Biolex Therapeutics today announced successful results from the Phase 1
clinical trial of Locteron, a product the company is co-developing with OctoPlus
(Leiden, the Netherlands)."
Novelos Therapeutics IND for Novel Hepatitis C Drug is Accepted by FDA; Company
Is on Track to Begin Patient Enrollment by July 2006
"Novelos Therapeutics, Inc., a biotechnology company focused on the development
of therapeutics to treat cancer and hepatitis, today announced that the Food and
Drug Administration (FDA) accepted Novelos' Investigational New Drug Application
(IND) for NOV-205, its second clinical stage compound. The initial U.S.-based
Phase 1b trial will evaluate NOV-205 as monotherapy for chronic hepatitis C
genotype 1 patients who have failed pegylated interferon plus ribavirin
therapy."
Transition Therapeutics reports positive data from hepatitis C trial
"Testing of a hepatitis C drug under development by Transition Therapeutics Inc.
has returned positive results, the drug company said Friday."
AVI
BioPharma Updates On Hepatitis C Virus Clinical Trial Status - Quick Facts
"On Thursday, AVI BioPharma. updated on the status of its multicenter study in
patients with chronic active hepatitis C virus infection. The company said that
the trial is designed to assess the safety, tolerability, pharmacokinetics and
viral response to treatment with AVI's proprietary NEUGENE antisense compound
AVI-4065 among healthy volunteers and patients with HCV."
Collaborative Financing From Symphony Capital Partners, LP Designed to Advance
Next-Generation TLR-Agonist Pipeline
"Dynavax Technologies announced an agreement with Symphony Capital Partners, LP
and its co-investors to provide $50 million of committed capital to advance
Dynavax's ISS-based cancer, hepatitis B and hepatitis C therapeutic programs
through clinical development."
New Jersey Considers Bills to Curb HIV and Hepatitis C
Drug Policy Alliance: New
Jersey Considers Bills to Curb HIV and Hepatitis C
"In a state with some of
the highest rates of HIV and hepatitis C spread by contaminated syringes, Drug
Policy Alliance's New Jersey office is working hard for passage of syringe
access legislation."
Trial to test Cangene's WinRho(R) SDF in hepatitis C patients
"Cangene today reports the beginning of a clinical trial at Weill Medical
College of Cornell University in New York City that will test Cangene's WinRho(R)
SDF in patients infected with hepatitis C virus (HCV)."
Occupational hazard; health care workers have more Hepatitis C
"Health care workers may get infected by the Hepatitis C virus if precautions
are not taken in disposing needles and other contaminated materials, according
to a new study which found that prevalence of virus was almost double in health
care workers in comparison to general population."
Musicians Raise Awareness of Hepatitis C in Missouri - Springfield and Columbia
Musicians Join Kelly's Lot to help The Missouri Hepatitis C Alliance Raise
Awareness of Hep C
"The Missouri Hepatitis C Alliance (MOHCA) is proud to announce an "Awareness
and Screening" program with three concerts by blues and roadhouse rock band
Kelly's Lot, national spokesband for the national Hep C Coalition."
Health Risks Shadow EMTs
"The face and hand protections are as much a part of a county ambulance's
equipment as oxygen and a backboard. Breathing masks guard against coughed-up
blood and saliva; eye goggles and face masks do the same. Disposable rubber
gloves are almost a part of the uniform. Older paramedics remember a time when
those safeguards weren't there, when they dove in at traumatic scenes
bare-handed and inhaled particles from infected lungs without worrying about the
tiny pathogens in the blood of the people they treated."
Activists: Hepatitis C clinical trial unfairly excludes blacks
"Two advocacy groups are blasting the decision by pharmaceutical company
Schering-Plough to exclude African-Americans from a clinical trial of its
experimental hepatitis C treatment, a decision the company says was needed to
better gauge the efficacy of the medications, The [Newark] Star-Ledger reports."
County Council to examine controversial needle exchange program
"Yesterday, more than 100 people walked through the parking lot of the Allegheny
County Health Department, entered one of the building's narrow hallways, and got
fresh supplies of the alcohol swabs, syringes and needles they need to inject
illegal drugs into their bloodstream. Proponents would say that Prevention Point
Pittsburgh's needle exchange program is an example of a public health measure
that has been successfully used around the country to limit the spread of
dangerous infections like HIV and hepatitis C."
Safety of nation's blood supply a prime concern for hemophiliacs
"The first people hurt when the nation's blood supply gets tainted are likely to
be those whose lives depend on transfusions. That's why blood safety is a major
concern of the more than 400 people with hemophilia and other clotting disorders
who are attending a national conference in St. Louis starting today."
Clinical Trials, Cohort Studies, Pilot Studies
Hepatitis C virus infection in a resident elderly population: A
10-year follow-up study.
Monica F, et al. Dig Liver Dis. 2006 Apr 14; [Epub ahead of print]
Majority of patients with hepatitis C express physical, mental, and social
difficulties with antiviral treatment. Zickmund SL, et al. Eur J Gastroenterol
Hepatol. 2006 Apr;18(4):381-8.
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin
nonresponder patients. Taliani G, et al. Gastroenterology. 2006
Apr;130(4):1098-106.
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72
weeks of peginterferon-alfa-2a plus ribavirin. Berg T, et al.
Gastroenterology.
2006 Apr;130(4):1086-97.
Consensus interferon and ribavirin for patients with chronic hepatitis C and
failure of previous interferon-alpha therapy. Bocher WO, et al. Liver Int. 2006
Apr;26(3):319-25.
Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis
C in end-stage renal disease patients on hemodialysis. Rocha CM, et al. Liver
Int. 2006 Apr;26(3):305-10.
Early identification of HCV genotype 1 patients responding to 24 weeks
peginterferon alpha-2a (40 kd)/ribavirin therapy. Jensen DM, et al.
Hepatology.
2006 Apr 20;43(5):954-960 [Epub ahead of print]
Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Kamal SM, et al.
Hepatology. 2006 Apr 20;43(5):923-931 [Epub ahead of print]
Steatosis and progression of fibrosis in untreated patients with chronic
hepatitis C infection.
Perumalswami P, et al. Hepatology. 2006 Apr;43(4):780-7.
Progression of fibrosis in hepatitis C with and without schistosomiasis:
correlation with serum markers of fibrosis. Kamal SM, et al. Hepatology. 2006
Apr;43(4):771-9.
Similarities and differences in outcomes of cirrhosis due to nonalcoholic
steatohepatitis and hepatitis C.
Sanyal AJ, et al. Hepatology. 2006 Apr;43(4):682-9.
Black patients with chronic hepatitis C have a lower sustained viral response
rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this
is not explained by more frequent dose reductions of interferon and ribavirin*. Brau N, et al. J Viral
Hepat. 2006 Apr;13(4):242-9.
Non-response to antiviral therapy is associated with obesity and increased
hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients
with chronic hepatitis C, viral genotype 1. Walsh MJ, et al.
Gut. 2006 Apr;55(4):529-35. Epub 2005 Nov 18.
Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase
Levels. Shiffman ML, et al. Clin Gastroenterol Hepatol. 2006 Apr 19; [Epub ahead
of print]
Assessment of liver fibrosis progression in patients with chronic hepatitis C
and normal alanine aminotransferase values: The role of AST to the platelet
ratio index. Fabris C, et al. Clin Biochem. 2006 Apr;39(4):339-43. Epub 2006 Feb
20.
Basic And Applied Science, Pre-Clinical Studies
Oval cells in hepatitis B virus-positive and hepatitis C
virus-positive liver cirrhosis: histological and ultrastructural study. Sun C,
Jin XL, Xiao JC. Histopathology. 2006 Apr;48(5):546-55.
Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo:
implications of HCV lymphotropism. Pal S, et al. Gastroenterology. 2006
Apr;130(4):1107-16.
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of
hepatitis C virus replication in vitro. Paeshuyse J, et al. Hepatology. 2006
Apr;43(4):761-70.
Antiproliferative effects of interferon alpha on hepatic progenitor cells in
vitro and in vivo.
Lim R, et al. Hepatology. 2006 Apr 20;43(5):1074-1083 [Epub ahead of print]
Genomic response to interferon-alpha in chimpanzees: Implications of rapid
downregulation for hepatitis C kinetics. Lanford RE, Guerra B, Lee H, Chavez D,
Brasky KM, Bigger CB. Hepatology. 2006 Apr 20;43(5):961-972 [Epub ahead of
print]
The interaction of natural hepatitis C virus with human scavenger receptor
SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. Maillard P, FASEB J.
2006 Apr;20(6):735-7. Epub 2006 Feb 13.
Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis
in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients
during interferon-alpha/beta treatment.
Yamaji K, et al. Cancer Immunol Immunother. 2006 Apr;55(4):394-403. Epub 2005
Jul 22.
Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV
and HCV infection.
Meuleman P, et al. Clin Chim Acta. 2006 Apr;366(1-2):156-62. Epub 2005 Oct 25.
Hepatitis C virus (HCV) core protein enhances the immunogenicity of a
co-delivered DNA vaccine encoding HCV structural antigens in mice. Alvarez-Lajonchere
L, et al. Biotechnol Appl Biochem. 2006 Apr;44(Pt 1):9-17.
Expression and processing of hepatitis C virus structural proteins in Pichia
pastoris yeast.
Martinez-Donato G, et al. Biochem Biophys Res Commun. 2006 Apr 7;342(2):625-31.
Epub 2006 Feb 8.
Role of p38 MAPK and RNA-dependent Protein Kinase (PKR) in Hepatitis C Virus
Core-dependent Nuclear Delocalization of Cyclin B1. Spaziani A, Alisi A, Sanna
D, Balsano C. J Biol Chem. 2006 Apr 21;281(16):10983-9. Epub 2006 Jan 30.
HIV/HCV Coinfection
Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in
HIV-infected Patients.
Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr. J Acquir Immune
Defic Syndr. 2006 Apr 24; [Epub ahead of print]
Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in
Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and
Along Gender. Rodriguez-Torres M, et al. J Clin Gastroenterol. 2006
Apr;40(4):358-366.
Importance of hepatitis C coinfection in the development of QT prolongation in
HIV-infected patients.
Nordin C, et al. J Electrocardiol. 2006 Apr;39(2):199-205. Epub 2005 Nov 28.
Gene Expression Profiles in Hepatitis C Virus (HCV) and HIV Coinfection: Class
Prediction Analyses before Treatment Predict the Outcome of Anti-HCV Therapy
among HIV-Coinfected Persons.
Lempicki RA, et al. J Infect Dis. 2006 Apr 15;193(8):1172-7. Epub 2006 Mar 13.
Impact of Hepatitis C Virus Coinfection on Response to Highly Active
Antiretroviral Therapy and Outcome in HIV-Infected Individuals: A Nationwide
Cohort Study. Weis N, et al. Clin Infect Dis. 2006 May 15;42(10):1481-7. Epub
2006 Apr 12.
Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C
virus (HCV) infection: assessment using transient elastometry and the role of
HCV genotype 3. Barreiro P, et al. Clin Infect Dis. 2006 Apr 1;42(7):1032-9.
Epub 2006 Feb 21.
HCV and HIV infection and co-infection: injecting drug use and sexual behavior,
AjUDE-Brasil I Project.
Zocratto KB, et al. Cad Saude Publica. 2006 Apr;22(4):839-848. Epub 2006 Apr 5.
Efficacy and Safety of Pegylated Interferon-alpha2b Plus Ribavirin for the
Treatment of Chronic Hepatitis C in HIV-Infected Patients. Santin M, et al. AIDS
Res Hum Retroviruses. 2006 Apr;22(4):315-20.
Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C
virus. Saadoun D, Aaron L, Resche-Rigon M, Pialoux G, Piette JC, Cacoub P;
GERMIVIC Study Group. AIDS. 2006 Apr 4;20(6):871-7.
Racial difference in mortality among U.S. veterans with HCV/HIV coinfection.
Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang KM. Am J Gastroenterol.
2006 Apr;101(4):760-7. Epub 2006 Feb 22.
Complementary And Alternative Therapies
Prediagnostic level of serum retinol in relation to reduced risk of
hepatocellular carcinoma. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. J Natl Cancer
Inst. 2006 Apr 5;98(7):482-90.
Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang. Hsu
LM, Huang YS, Tsay SH, Chang FY, Lee SD. J Chin Med Assoc. 2006 Feb;69(2):86-8.
Polyphenols and gastrointestinal diseases. Dryden
GW, Song M, McClain C. Curr
Opin Gastroenterol. 2006 Mar;22(2):165-70.
Miscellaneous Works
Assessing patients' understanding of hepatitis C virus infection and its impact
on their lifestyle.
Fabris P, et al. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1161-70.
Patient age is a strong independent predictor of 13C-aminopyrine breath test
results: a comparative study with histology, duplex-Doppler and a laboratory
index in patients with chronic hepatitis C virus infection.
Schneider AR, et al. Clin Exp Pharmacol Physiol. 2006 Apr;33(4):300-4.
Effectiveness of a Screening Program for Hepatitis C. Cheung RC, Cunningham BA,
Cooper AD. Dig Dis Sci. 2006 Apr 27; [Epub ahead of print]
Analysis of a hepatitis C screening programme for US veterans. Zuniga IA, et al. Epidemiol Infect. 2006 Apr;134(2):249-57.
Relationship between hepatitis C and chronic kidney disease: results from the
Third National Health and Nutrition Examination Survey. Tsui JI, Vittinghoff E,
Shlipak MG, O'Hare AM. J Am Soc Nephrol. 2006 Apr;17(4):1168-74. Epub 2006 Mar
8.
Socio-economic characteristics, quality of life, and state of knowledge of
patients with hepatitis C viral infection in Germany - socio-economical aspects
in hepatitis C.[Article in German] Niederau C, Bemba G, Kautz A. Z
Gastroenterol.
2006 Apr;44(4):305-17.
Provider-patient in-office discussions of response to hepatitis C antiviral
therapy and impact on patient comprehension. Hamilton HE, Nelson M, Martin P, Cotler
SJ. Clin Gastroenterol Hepatol. 2006 Apr;4(4):507-13.
|
  |
